Literature DB >> 3825890

Role of exercise thallium-201 myocardial perfusion scintigraphy in predicting prognosis in suspected coronary artery disease.

J H Koss, S M Kobren, A M Grunwald, M M Bodenheimer.   

Abstract

While exercise thallium imaging has improved sensitivity and specificity for detection of coronary artery disease (CAD), its predictive value for morbid cardiac events is unclear. Of 532 consecutive patients who underwent exercise thallium imaging, follow-up was complete in 515 (97%) after an average of 36 months (range 31 to 48). Two hundred six patients had an abnormal exercise thallium response and 309 had a normal response. Twenty morbid cardiac events occurred (13 deaths and 7 acute myocardial infarctions [AMI]). Of the 13 patients who died, 12 had abnormal thallium results. Overall, 5.8% of the patients with abnormal thallium results died, in contrast to 0.3% of patients with normal results. Of the 7 patients who had a nonfatal AMI, 3 had abnormal exercise thallium results. Moreover, similar proportions of patients (1.4% and 1.3%) with normal and abnormal exercise thallium results had nonfatal AMI. Presence or absence of pathologic Q waves and inclusion of exercise electrocardiographic results did not significantly alter the results. Thus, although a normal exercise thallium response significantly reduces the likelihood of cardiovascular death, its predictive value for nonfatal AMI is limited. Moreover, the relatively low event rate for patients with a positive exercise thallium response further limits its prognostic value.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3825890     DOI: 10.1016/0002-9149(87)91163-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Chest Pain with Normal Thallium-201 Myocardial Perfusion Image - Is It Really Normal?

Authors:  Pang-Yen Liu; Wen-Yu Lin; Li-Fan Lin; Chin-Sheng Lin; Wei-Shiang Lin; Shu-Meng Cheng; Shih-Ping Yang; Jun-Ting Liou
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

2.  American Society of Nuclear Cardiology project on myocardial perfusion imaging: measuring outcomes in response to emerging guidelines.

Authors:  R S Gibbons
Journal:  J Nucl Cardiol       Date:  1996 Sep-Oct       Impact factor: 5.952

3.  Comparison of stress-only vs. stress/rest with technetium-99m methoxyisobutylisonitrile myocardial perfusion imaging.

Authors:  D F Worsley; A Y Fung; D B Coupland; C G Rexworthy; G P Sexsmith; B C Lentle
Journal:  Eur J Nucl Med       Date:  1992

4.  One-year prognosis of patients with normal planar or single-photon emission computed tomographic technetium 99m-labeled sestamibi exercise imaging.

Authors:  K Raiker; A J Sinusas; F J Wackers; B L Zaret
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

5.  Prognostic value of myocardial hypoperfusion indexes in patients with suspected or known coronary artery disease.

Authors:  M Petretta; A Cuocolo; A Carpinelli; E Nicolai; G Valva; V Bianchi; L Salemme; M Salvatore; D Bonaduce
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

6.  Patients with a normal exercise thallium-201 myocardial scintigram: always a good prognosis?

Authors:  W P Oosterhuis; A Breeman; M G Niemeyer; A H Zwinderman; A F Kuijper; E E van der Wall; J G Tijssen; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1993-02

7.  Left ventricular mass index and coronary artery disease in hypertensive black males.

Authors:  F C Robinson; K Satterwhite; C Potter; K Craddock; S A Beyoglu
Journal:  J Natl Med Assoc       Date:  1993-06       Impact factor: 1.798

8.  Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis.

Authors:  Sachin M Navare; Jeff F Mather; Leslee J Shaw; Michael S Fowler; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2004 Sep-Oct       Impact factor: 5.952

Review 9.  Myocardial scintigraphy--25 years after start.

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1988
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.